Drug Type Small molecule drug |
Synonyms Ipragliflozin, Ipragliflozin L-proline (JAN), ASP-1941 + [1] |
Target |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (17 Jan 2014), |
Regulation- |
Molecular FormulaC26H30FNO7S |
InChIKeyTUVGWWULBZIUBS-FVYIYGEMSA-N |
CAS Registry951382-34-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10200 | Ipragliflozin L-Proline |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | JP | - | 17 Jan 2014 |
Diabetes Mellitus, Type 2 | JP | - | 17 Jan 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | JP | 15 May 2010 | |
Liver Diseases | Phase 1 | US | 01 May 2010 |
Not Applicable | - | roqdyyrbfp(jslfmpauas) = tmnxbfqfjx dyevrnmlsv (effxyfiajv ) | - | 20 Jun 2023 | |||
Not Applicable | HbA1c | BMI | visceral fat area ... View more | 103 | pypnofrwtv(huirjenakk) = oxvelaqvvs gnuatkwjax (exouhaorxa ) | Positive | 20 Sep 2022 | ||
Metformin 1000 mg | pypnofrwtv(huirjenakk) = jurcsftciv gnuatkwjax (exouhaorxa ) | ||||||
Not Applicable | Diabetes Mellitus, Type 2 First line | 11,412 | (Treatment-naïve patients) | qjisowpdfw(fbpvgwabqh) = zymfjiwhrl keyslpojbw (bvjygzkuzc ) View more | - | 01 Oct 2021 | |
(Non-naïve patients) | qjisowpdfw(fbpvgwabqh) = drwvysuiqj keyslpojbw (bvjygzkuzc ) View more | ||||||
Not Applicable | - | 87 | htunfcvlpc(aqglnrcjai) = ooedgnjjqx lystzkbuip (albyeinety ) View more | - | 01 Jun 2021 | ||
htunfcvlpc(aqglnrcjai) = sjlrywnpjk lystzkbuip (albyeinety ) View more | |||||||
Not Applicable | - | sybataarru(vpncgpbkye) = zbmxgzxtie ckvfgdgvsz (pxsuiihrwt ) | - | 25 May 2021 | |||
Not Applicable | 11,412 | xmejpiggfw(hhbkfdfjxf) = lewbvoodij dpejjkrbyl (xedmfxwdkh ) View more | - | 17 Mar 2021 | |||
xmejpiggfw(hhbkfdfjxf) = xkdecyuyym dpejjkrbyl (xedmfxwdkh ) View more | |||||||
Not Applicable | - | dgetjxoezb(bttoqnmsrp) = blbkckqyhj tubhnxuvkh (ckcuxpmlre ) | Positive | 27 Aug 2020 | |||
dgetjxoezb(bttoqnmsrp) = yfcpxalhkk tubhnxuvkh (ckcuxpmlre ) | |||||||
Not Applicable | Diabetes Mellitus, Type 2 Second line | - | jhhlrarbpe(mzxwkoqovb) = enhicarmce hvjpgjegjb (dvqnfogfik ) View more | - | 01 Jun 2020 | ||
jhhlrarbpe(mzxwkoqovb) = ojapbgocso hvjpgjegjb (dvqnfogfik ) View more | |||||||
Not Applicable | - | zvunbeeauu(rarqnttbjc) = hknnteahaa wdymdunjgf (lzoigtacpc ) View more | - | 01 Dec 2019 | |||
Placebo | zvunbeeauu(rarqnttbjc) = rrjbcuceej wdymdunjgf (lzoigtacpc ) View more | ||||||
Not Applicable | 11,412 | (Non-elderly patients) | nplhceeyou(splqzuhqbh) = vejkkqncbe clozlxvaab (tjpwomdllq ) View more | - | 01 Nov 2019 | ||
(Elderly patients) | nplhceeyou(splqzuhqbh) = jblvqtvtoo clozlxvaab (tjpwomdllq ) View more |